Skip to main content

New Therapeutic Approaches to Resistant Hypertension


Resistant hypertension is a common and growing clinical problem characterized by failure to achieve target blood pressure levels despite adequate use of at least three antihypertensive agents. Although numerous safe and effective pharmacologic therapies are available to treat elevated blood pressure, novel therapeutic approaches are warranted to improve the management and prognosis of patients with resistant hypertension. In this context, several lines of research have generated promising results based on both novel pharmacologic and device-based approaches that may more effectively treat resistant hypertension and its adverse consequences in the future.

This is a preview of subscription content, access via your institution.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Perkovic V, Huxley R, Wu Y, et al.: The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50:991–997.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003, 290:199–206.

    Article  PubMed  Google Scholar 

  3. 3.

    Sarafidis PA, Bakris GL: Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749–1757.

    Article  PubMed  Google Scholar 

  4. 4.

    Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105–1187.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Black HR, Elliott WJ, Grandits G, et al.: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073–2082.

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002, 4:393–404.

    Article  Google Scholar 

  7. 7.

    Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403–1419.

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    de Souza F, Muxfeldt E, Fiszman R, Salles G: Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147–152.

    Article  PubMed  Google Scholar 

  9. 9.

    Chapman N, Dobson J, Wilson S, et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839–845.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Wood JM, Maibaum J, Rahuel J, et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698–705.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1–E8.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012–1018.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Frampton JE, Curran MP: Aliskiren: a review of its use in the management of hypertension. Drugs 2007, 67:1767–1792.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417–1427.

    CAS  PubMed  Google Scholar 

  15. 15.

    Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.

    Article  CAS  PubMed  Google Scholar 

  16. 16.

    Solomon SD, Appelbaum E, Manning WJ, et al.: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530–537.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    McMurray JJ, Pitt B, Latini R, et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17–24.

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Solomon SD: Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with left ventricular dysfunction: ASPIRE. Presentation No: 3019-10, presented at American College of Cardiology 59th Annual Scientific Sessions. Atlanta, GA; March 14–16, 2010.

  19. 19.

    Fiebeler A, Nussberger J, Shagdarsuren E, et al.: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087–3094.

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Weber MA: Vasopeptidase inhibitors. Lancet 2001, 358:1525–1532.

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Kostis JB, Packer M, Black HR, et al.: Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004, 17:103–111.

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    •• Ruilope LM, Dukat A, Böhm M, et al.: Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, 375:1255–1266. This is the first study to report on the safety and BP-lowering effects of an ARB/neprilysin inhibitor combination.

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Brown MJ, Coltart J, Gunewardena K, et al.: Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107:167–173.

    Article  CAS  Google Scholar 

  24. 24.

    Ambuhl PM, Tissot AC, Fulurija A, et al.: A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63–72.

    Article  PubMed  Google Scholar 

  25. 25.

    • Tissot AC, Maurer P, Nussberger J, et al.: Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821–827. This study provides evidence of successful immunization against angiotensin II and associated BP-lowering effects.

    Article  CAS  PubMed  Google Scholar 

  26. 26.

    Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338:784–790.

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    Raichlin E, Prasad A, Mathew V, et al.: Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008, 52:522–528.

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15(7 Pt 1):583–589.

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Black HR, Bakris GL, Weber MA, et al.: Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007, 9:760–769.

    Article  CAS  Google Scholar 

  30. 30.

    •• Weber MA, Black H, Bakris G, et al.: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1423–1431. This study provides evidence for a potentially important role of endothelin antagonism in resistant hypertension.

    Article  CAS  PubMed  Google Scholar 

  31. 31.

    Lohmeier TE, Irwin ED, Rossing MA, et al.: Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004, 43:306–311.

    Article  CAS  PubMed  Google Scholar 

  32. 32.

    Illig KA, Levy M, Sanchez L, et al.: An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006, 44:1213–1218.

    Article  PubMed  Google Scholar 

  33. 33.

    • Lovett EG, Schafer J, Kaufman CL: Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:4626–4630. This article presents an overview of safety and efficacy data on carotid sinus stimulation in resistant hypertension.

    PubMed  Google Scholar 

  34. 34.

    Sanchez LA, Illig K, Levy M, et al.: Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Ann Vasc Surg 2010, 24:178–184.

    Article  PubMed  Google Scholar 

  35. 35.

    Heusser K, Tank J, Engeli S, et al.: Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010, 55:619–626.

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    Young KC, Teeters JC, Benesch CG, et al.: Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J Clin Hypertens (Greenwich) 2009, 11:555–563.

    Article  Google Scholar 

  37. 37.

    Campese VM: Neurogenic factors and hypertension in chronic renal failure. J Nephrol 1997, 10:184–187.

    CAS  PubMed  Google Scholar 

  38. 38.

    Ye S, Gamburd M, Mozayeni P, et al.: A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998, 11(6 Pt 1):723–728.

    Article  CAS  PubMed  Google Scholar 

  39. 39.

    Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002, 15:717–724.

    Article  CAS  PubMed  Google Scholar 

  40. 40.

    Campese VM: Neurogenic factors and hypertension in renal disease. Kidney Int 2000, 57(Suppl 75):S2–S6.

    Article  Google Scholar 

  41. 41.

    Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25(4 Pt 2):878–882.

    CAS  PubMed  Google Scholar 

  42. 42.

    Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995, 26:861–865.

    Article  CAS  PubMed  Google Scholar 

  43. 43.

    Smithwick RH, Thompson JE: Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953, 152:1501–1504.

    CAS  PubMed  Google Scholar 

  44. 44.

    Morrissey DM, Brookes VS, Cooke WT: Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953, 1(6757):403–408.

    Article  CAS  PubMed  Google Scholar 

  45. 45.

    Schlaich MP, Sobotka PA, Krum H, et al.: Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009, 54:1195–1201.

    Article  CAS  PubMed  Google Scholar 

  46. 46.

    •• Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275–1281. This study presents the first data on the safety and efficacy of a novel catheter-based approach to functionally denervate the human kidney, demonstrating a favorable safety profile and substantial and sustained reductions in BP.

    Article  PubMed  Google Scholar 

  47. 47.

    Schlaich MP, Sobotka PA, Krum H, et al.: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361:932–934.

    Article  CAS  PubMed  Google Scholar 

Download references


Dr. Schlaich, Dr. Krum, and Dr. Esler are principal investigators in clinical trials sponsored by Ardian, Inc. (NCT00483808 and NCT00551304 at Dr. Schlaich and Dr. Esler are supported by Senior Research Fellowships from the National Health & Medical Research Council (NHMRC) of Australia.

Author information



Corresponding author

Correspondence to Markus P. Schlaich.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schlaich, M.P., Krum, H. & Esler, M.D. New Therapeutic Approaches to Resistant Hypertension. Curr Hypertens Rep 12, 296–302 (2010).

Download citation


  • Resistant hypertension
  • Therapy
  • Renin
  • Aldosterone
  • Sympathetic
  • Renal nerves
  • Baroreflex